Core Laboratories (CLB) Equity Average (2022 - 2026)

Core Laboratories has reported Equity Average for 5 years, with the latest figure at $270.6 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 6.89% year-over-year to $270.6 million; the trailing twelve-month figure through Mar 2026 stood at $270.6 million (up 6.89% YoY), and the FY2025 full-year result was $259.2 million, up 8.73% from the prior year.
• Equity Average for Q1 2026 stood at $270.6 million, up from $268.7 million in the prior quarter.
• The five-year high for Equity Average was $270.6 million in Q1 2026, with the low at $178.5 million in Q3 2022.
• Historically, Equity Average has averaged $234.4 million across 5 years, with a median of $241.6 million in 2024.
• Annual changes were most pronounced in 2023 — Equity Average rose 25.76% — and 2025, when it climbed 5.62%.
• Core Laboratories' Equity Average stood at $183.4 million in 2022, then gained by 23.72% to $226.9 million in 2023, then gained by 12.1% to $254.4 million in 2024, then increased by 5.62% to $268.7 million in 2025, then rose by 0.71% to $270.6 million in 2026.
• The last three Equity Average figures came in at $270.6 million (Q1 2026), $268.7 million (Q4 2025), and $269.3 million (Q3 2025), per Business Quant data.